Radiation Dose Optimization in Diffuse Large B- Cell Lymphoma.

Summary

The purpose of this study is to compare standard dose radiation of 45 Gray(Gy) in 25 fractions in Non Hodgkin's Lymphoma- Diffuse Large B cell Lymphoma (NHL-DLBCL) to that of 36 Gy in 20 fractions. The role of radiation in NHL-DLBCL has been addressed in large cooperative trials showing improvement in overall survival and progression free survival with combined modality treatment. The doses of radiation used in these trials are heterogeneous ranging from 30-55 Gray(Gy). There is uncertainty about the optimal dose of radiation needed in aggressive lymphomas. A dose response phenomenon is known in Non- Hodgkin's Lymphoma. Late effects of higher dose radiation in the form of higher risk of stroke, myocardial infarction, thyroid abnormalities and secondary breast cancer are being increasingly identified. Hence it is essential to optimize the dose of radiotherapy for lower toxicity without compromising on efficacy.

Eligibility

Inclusion Criteria:

* Histological Diagnosis of NHL- DLBCL.
* Eligible for RT after R-CHOP.
* ECOG 0-3.
* 18 - 65 years.
* Stage I-IV.
* Patients should receive at least 4 cycles of R-CHOP chemotherapy.
* Patients with all extranodal disease except the ones mentioned in the exclusion criteria.
* Able to understand and willing to provide informed consent for participation in the trial.

Exclusion Criteria:

* HIV positive status.
* Relapse or progression of disease during chemotherapy.
* Prior history of chemotherapy
* Prior history of radiotherapy.
* Systemic lymphomas with CNS involvement.
* Primary extranodal Testicular Lymphomas.
* Primary extranodal central nervous system (CNS) Lymphomas.
* Primary extranodal Stomach DLBCL
* Primary extranodal Intestinal DLBCL
* Patients \>3 extranodal sites

Conditions2

Browse More Trials